Pneumoconiosis: Current Status and Future Prospects
Pneumoconiosis represents a group of heterogeneous occupational interstitial lung diseases caused by the inhalation of mineral dust, leading to lung dysfunction. The primary pathological features include chronic pulmonary inflammation and progressive pulmonary fibrosis, which can eventually result in death due to respiratory and/or heart failure. This disease is widespread globally and poses a significant threat to public health. The high incidence and mortality rates are attributed to inadequate occupational protection, the lack of early diagnostic methods, and effective treatments. This article provides a comprehensive review of the epidemiology, safeguard procedures, diagnosis, and treatment of pneumoconiosis, along with recent research advances and future prospects.
Epidemiology of Pneumoconiosis
Despite numerous measures implemented to protect workers from dust inhalation over the past few decades, pneumoconiosis remains a significant public health threat. According to the Global Burden of Disease studies, the worldwide prevalence of pneumoconiosis has shown a downward trend since 2015, yet there are still approximately 527,500 cases, with over 60,000 new patients reported globally in 2017. The mortality rate has remained high, with over 21,000 deaths annually since 2015.
Alarmingly, pneumoconiosis has re-emerged even in countries with highly developed healthcare systems and stringent workplace safety standards, such as the United States and Australia. This resurgence suggests that less developed countries with inadequate reporting systems may have many undiagnosed cases. Additionally, the fear of job loss discourages workers from undergoing physical examinations, leading to delayed detection of the disease. Consequently, the actual morbidity and mortality rates of pneumoconiosis are likely higher than reported.
Safeguard Procedures of Pneumoconiosis
The Occupational Safety and Health Administration (OSHA) revised the standards for occupational exposure to respirable crystalline silica (RCS) in 2016, limiting permissible exposure to 50 mg/m3 and imposing stricter exposure limits on specific industries. OSHA estimates that these regulations will significantly reduce the risk of health impairment. The revised standards also include provisions for controlling dust concentration, exposure assessment, using protective tools, regular physical examinations, and preserving pathological records.
Despite these measures, silicosis has emerged in new industries such as denim jeans manufacturing and artificial stone (AS) processing. Sandblasting in denim production and cutting/polishing AS result in high concentrations of RCS exposure, leading to rapid progression of accelerating silicosis, particularly among young workers. The development of nanotechnology has also introduced new risks, as studies suggest that nano-silica can cause lung inflammation and fibrosis.
Diagnosis of Pneumoconiosis
Current Diagnostic Methods
The screening for pneumoconiosis primarily relies on a history of exposure to harmful dusts and chest radiography. The International Labour Organization (ILO) International Classification of Radiograph of Pneumoconiosis (ILO/ICRP) provides the current diagnostic criteria, last revised in 2011. This revision introduced digital standard images and specified the quality of diagnostic monitors. The National Institute of Occupational Safety and Health (NIOSH) certifies technicians for reading digital radiographs.
High-resolution computed tomography (HRCT) is more sensitive than chest X-rays for detecting early signs of pneumoconiosis. The International Classification of HRCT for Occupational and Environmental Respiratory Diseases (ICOERD) has developed a list of diagnoses for occupational and environmental-related lung diseases. However, the ILO classification remains the global standard due to the lack of a unified HRCT classification.
Pulmonary function tests (PFT) are used to assess dyspnea, distinguish between obstructive and restrictive diseases, and evaluate disease severity. Laboratory examinations, such as bronchoalveolar lavage fluid (BALF) analysis, help exclude similar pulmonary diseases by observing alveolar sediment.
Potential New Diagnostic Methods
Electrical impedance tomography (EIT) shows promise for early diagnosis by detecting changes in electrical conductivity before clinical symptoms appear. EIT is harmless and allows for dynamic monitoring, making it suitable for clinical practice once diagnostic criteria are established.
Three-dimensional magnetopneumography magnetic dipole model (3D-MPG-MDM) can non-invasively track the amount and distribution of particles in the lungs, aiding in the early diagnosis of pneumoconiosis caused by metal particles. However, its safety, sensitivity, and specificity require further evaluation.
Epigenetic pathways, particularly microRNA (miRNA), offer potential as clinical diagnostic biomarkers. miRNA-155 expression levels correlate with lung fibrosis in mice, and its stability in serum makes it suitable for clinical applications. Advances in miRNA research could provide biomarkers for early pneumoconiosis diagnosis.
Treatment of Pneumoconiosis
Current Treatments
Established clinical treatments for pneumoconiosis are limited. The only life-saving option for end-stage pneumoconiosis is lung transplantation, with a three-year survival rate of 76%. However, the median survival post-transplantation is only six to seven years, and the procedure is restricted by the availability of donor lungs, high costs, and significant risks.
Integrated treatments focus on alleviating common symptoms such as cough, chest pain, and shortness of breath. Managing complications like respiratory infections, tuberculosis, chronic obstructive pulmonary disease, and pneumothorax, along with rehabilitative exercises, can improve lung function and quality of life.
Whole lung lavage removes phlegm, secretions, and dust or fibrotic cytokines from the airways, potentially delaying disease progression. This procedure is most effective in the early stages of pneumoconiosis but lacks evidence of long-term benefits on pulmonary function or fibrosis.
Potential Therapies
New Drugs
Several drugs have shown therapeutic potential for pneumoconiosis. Pirfenidone, an anti-fibrosis drug for idiopathic pulmonary fibrosis (IPF), inhibits pulmonary fibrosis by regulating fibroblast growth factor (FGF), connective tissue growth factor (CTGF), transforming growth factor (TGF)-β, oxidative factors, and pro-inflammatory factors. Experimental studies on silica-induced lung fibrosis in rats demonstrated that pirfenidone slows epithelial-mesenchymal transition (EMT) by down-regulating vimentin and up-regulating E-cadherin.
Other drugs with potential anti-inflammatory and anti-fibrotic effects include hydroxychloroquine, corticosteroids, infliximab, N-acetylcysteine, nicorandil, and carvedilol. Traditional Chinese medicine extracts like dioscin, astragaloside IV, kaempferol, tanshinone IIA, and dihydrotanshinone have shown promise in alleviating silicosis in animal models.
Stem Cell Therapy
Stem cell therapy holds significant potential for treating pneumoconiosis. Preclinical studies have demonstrated that mesenchymal stem cells (MSCs) can inhibit inflammation and fibrosis in silicosis models. Early-phase clinical trials have shown that combining MSCs with hepatocyte growth factor (HGF) improves symptoms and lung function in silicosis patients.
Induced pluripotent stem (iPS) cells offer a method for developing personalized treatments by reprogramming mature cells to an embryonic state and culturing mature cell types, including lungs, in the laboratory. Despite promising results, stem cell therapy faces challenges related to safety, efficacy, technical barriers, ethical issues, and high costs.
Future Research Prospects
Emerging Techniques
High-throughput omics technology, bioinformatics, and gene-editing technologies like CRISPR/Cas9 show promise for in-depth pneumoconiosis research. Genomics studies have identified single nucleotide polymorphisms associated with pneumoconiosis susceptibility. Epigenomics studies suggest that miRNAs could serve as non-invasive biomarkers. Transcriptomics and proteomics have identified key targets and signaling pathways involved in pneumoconiosis.
Integrating omics and spaceomics technologies may provide comprehensive approaches to studying pneumoconiosis. Gene-editing technologies allow for precise modifications of target genes, accelerating the discovery of new genes and proteins with important functions.
New Targets
Inflammation and fibrosis are the primary pathophysiological mechanisms of pneumoconiosis. Immune inflammatory pathways, particularly those involving macrophages, T and B lymphocytes, and cytokines, are key therapeutic targets. Studies have shown that antagonizing macrophage receptor with collagenous structure (MARCO), inhibiting NLRP3 inflammasome, and blocking signaling pathways like CD44-RhoA-YAP, RhoA/Rho kinase, and FAS-caspase-8 can alleviate pneumoconiosis in animal models.
miRNAs regulate gene transcription and have shown potential in inhibiting silicosis fibrosis. Further research into multiple targets and complex cell networks is needed to develop effective treatments for pneumoconiosis.
Summary
Pneumoconiosis remains a significant global health threat due to inadequate dust prevention, early diagnostic methods, and effective treatments. Recent advances in high-throughput omics, bioinformatics, and gene-editing technologies offer hope for identifying new biomarkers and therapeutic targets. Stem cell therapy and new drugs like pirfenidone show promise for improving patient outcomes. Continued research into the pathological mechanisms of pneumoconiosis is essential for developing effective prevention and treatment strategies.
doi.org/10.1097/CM9.0000000000001461
Was this helpful?
0 / 0